1. Home
  2. EVG vs NTHI Comparison

EVG vs NTHI Comparison

Compare EVG & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

EVG

Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

HOLD

Current Price

$10.75

Market Cap

142.9M

Sector

Finance

ML Signal

HOLD

Logo NeOnc Technologies Holdings Inc.

NTHI

NeOnc Technologies Holdings Inc.

HOLD

Current Price

$4.49

Market Cap

114.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVG
NTHI
Founded
N/A
2008
Country
United States
United States
Employees
N/A
5
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
142.9M
114.6M
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
EVG
NTHI
Price
$10.75
$4.49
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
29.6K
94.9K
Earning Date
01-01-0001
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.40
$3.71
52 Week High
$11.45
$12.99

Technical Indicators

Market Signals
Indicator
EVG
NTHI
Relative Strength Index (RSI) 52.13 45.30
Support Level $10.62 $4.49
Resistance Level $10.94 $5.78
Average True Range (ATR) 0.11 0.28
MACD 0.01 0.01
Stochastic Oscillator 52.17 26.46

Price Performance

Historical Comparison
EVG
NTHI

About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.

About NTHI NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.

Share on Social Networks: